Literature DB >> 26590051

Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis.

Kiyoki Kitagawa1, Kengo Furuichi2,3,4, Akihiro Sagara5,6, Yasuyuki Shinozaki5,6, Shinji Kitajima5,6, Tadashi Toyama5,6, Akinori Hara5,6, Yasunori Iwata5,6,7, Norihiko Sakai8,5,6, Miho Shimizu5,6, Shuichi Kaneko6, Takashi Wada5,7.   

Abstract

BACKGROUND: The prevention of relapse and infection complications during remission maintenance therapy is required to improve the prognosis of patients with microscopic polyangiitis (MPA) showing rapidly progressive glomerulonephritis (RPGN). The clinicopathological characteristics of patients with ANCA-positive MPA were examined to determine the risk factors for relapse or infectious complications after remission induction therapy. PATIENTS AND METHODS: The study population consisted of 52 patients diagnosed as ANCA-positive MPA showing RPGN from 2002 to 2012, after publication of the Japanese guideline for RPGN. The clinicopathological findings were examined between the presence and absence of relapse or infectious complications.
RESULTS: The value of vasculitis damage index (VDI) was high for the relapse group and VDI value was identified as the leading factor associated with relapse [hazard ratio (HR) 3.36, 95 % confidence interval (CI) 1.58-7.12, P < 0.01]. On the other hand, the values of Birmingham Vasculitis Activity Score, clinical grade category of RPGN at diagnosis, and VDI at remission were high in the infectious group. Furthermore, clinical grade category of RPGN was the leading factor associated with infectious complications (HR 5.30, 95 % CI 1.41-19.9, P = 0.01).
CONCLUSION: The disease activity at diagnosis and severity of organ damage at remission were associated with relapse and infectious complications during remission maintenance therapy and infectious complication affected kidney survival and all-cause mortality in patients with ANCA-positive MPA exhibiting RPGN.

Entities:  

Keywords:  Infection; Microscopic polyangiitis (MPA); Prognosis; Rapidly progressive glomerulonephritis (RPGN); Relapse

Mesh:

Substances:

Year:  2015        PMID: 26590051     DOI: 10.1007/s10157-015-1199-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  16 in total

1.  Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.

Authors:  Michael Walsh; Peter A Merkel; Alfred Mahr; David Jayne
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

3.  EULAR recommendations for the management of primary small and medium vessel vasculitis.

Authors:  C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

4.  BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

Authors:  C Lapraik; R Watts; P Bacon; D Carruthers; K Chakravarty; D D'Cruz; L Guillevin; L Harper; D Jayne; R Luqmani; J Mooney; D Scott
Journal:  Rheumatology (Oxford)       Date:  2007-09-05       Impact factor: 7.580

5.  Relapse and its remission in Japanese patients with idiopathic membranous nephropathy.

Authors:  Shinji Kitajima; Kengo Furuichi; Norihiko Sakai; Akihiro Sagara; Yasuyuki Shinozaki; Tadashi Toyama; Yasunori Iwata; Miho Shimizu; Hitoshi Yokoyama; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2014-06-24       Impact factor: 2.801

6.  Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial.

Authors:  Wladimir M Szpirt; James G Heaf; Jørgen Petersen
Journal:  Nephrol Dial Transplant       Date:  2010-06-24       Impact factor: 5.992

7.  Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.

Authors:  Toshiko Ito-Ihara; Takahiko Ono; Fumiaki Nogaki; Katsuo Suyama; Mari Tanaka; Satomi Yonemoto; Atsushi Fukatsu; Toru Kita; Kazuo Suzuki; Eri Muso
Journal:  Nephron Clin Pract       Date:  2005-09-19

8.  Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients.

Authors:  Midori Hasegawa; Atsushi Ohashi; Nao Kabutan; Saori Hiramatsu; Masao Kato; Kazutaka Murakami; Makoto Tomita; Kunihiro Nabeshima; Yoshiyuki Hiki; Satoshi Sugiyama
Journal:  Ther Apher Dial       Date:  2006-10       Impact factor: 1.762

9.  Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.

Authors:  Valérie Martinez; Pascal Cohen; Christian Pagnoux; Stéphane Vinzio; Alfred Mahr; Luc Mouthon; Laurent Sailler; Claire Delaunay; Alain Sadoun; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2008-01

10.  Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis.

Authors:  Kiyoki Kitagawa; Kengo Furuichi; Yasuyuki Shinozaki; Tadashi Toyama; Shinji Kitajima; Akinori Hara; Yasunori Iwata; Norihiko Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-04-10       Impact factor: 2.801

View more
  6 in total

1.  Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis.

Authors:  Huijuan Wang; Chao Zhang; Zhaohui Tong; Xiaoning Bu
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Characteristics and prognosis of microscopic polyangiitis with bronchiectasis.

Authors:  Hiroki Tashiro; Koichiro Takahashi; Masahide Tanaka; Kazutoshi Komiya; Tomomi Nakamura; Shinya Kimura; Yoshifumi Tada; Naoko Sueoka-Aragane
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

3.  Infection-related hospitalization after intensive immunosuppressive therapy among lupus nephritis and ANCA glomerulonephritis patients.

Authors:  Peihong Yin; Jianbo Li; Qiong Wen; Yagui Qiu; Wenyi Liang; Junxian Wang; Jing Yu; Zhong Zhong; Xiao Yang; Xueqing Yu; Qing Ye; Fengxian Huang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Michiko Morishita; Ken-Ei Sada; Yoshinori Matsumoto; Keigo Hayashi; Yosuke Asano; Sumie Hiramatsu Asano; Keiji Ohashi; Yoshia Miyawaki; Eri Katsuyama; Haruki Watanabe; Tomoko Kawabata; Jun Wada
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

5.  Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan.

Authors:  Hirokazu Sugiyama; Makoto Yamaguchi; Takayuki Katsuno; Shiho Iwagaitsu; Hironobu Nobata; Hiroshi Kinashi; Shogo Banno; Masahiko Ando; Yoko Kubo; Takuji Ishimoto; Yasuhiko Ito
Journal:  BMC Geriatr       Date:  2021-03-09       Impact factor: 3.921

6.  Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.

Authors:  Liu Yang; Honglang Xie; Zhengzhao Liu; Yinghua Chen; Jinquan Wang; Haitao Zhang; Yongchun Ge; Weixin Hu
Journal:  BMC Nephrol       Date:  2018-06-14       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.